Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Perhexiline | hsa00190 | Oxidative phosphorylation | 1.03E-05 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Perhexiline | hsa00270 | Cysteine and methionine metabolism | 4.56E-02 | 3 | Q99707, P26358, Q9UHY7 | MTR, DNMT1, ENOPH1 | More | | Perhexiline | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Perhexiline | hsa00591 | Linoleic acid metabolism | 8.00E-04 | 1 | P11712 | CYP2C9 | More | | Perhexiline | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Perhexiline | hsa00920 | Sulfur metabolism | 1.65E-02 | 1 | Q16762 | TST | More | | Perhexiline | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Perhexiline | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Perhexiline | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | Perhexiline | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | Perhexiline | hsa03013 | RNA transport | 2.89E-02 | 7 | O14980, Q09161, Q7Z3B4, P47813, Q14152, O75822, Q14240 | XPO1, NCBP1, NUP54, EIF1AX, EIF3A, EIF3J, EIF4A2 | More | | Perhexiline | hsa03022 | Basal transcription factors | 1.47E-03 | 3 | P20226, O00268, Q15544 | TBP, TAF4, TAF11 | More | | Perhexiline | hsa04010 | MAPK signaling pathway | 1.53E-02 | 2 | Q9H2K8, Q12933 | TAOK3, TRAF2 | More | | Perhexiline | hsa04064 | NF-kappa B signaling pathway | 3.99E-02 | 6 | P10415, Q13489, P29965, Q9UDY8, Q8WV28, Q13315 | BCL2, BIRC3, CD40LG, MALT1, BLNK, ATM | More | | Perhexiline | hsa04070 | Phosphatidylinositol signaling system | 3.47E-02 | 4 | P0DP23, Q14643, P23743, P17252 | CALM1, ITPR1, DGKA, PRKCA | More | | Perhexiline | hsa04071 | Sphingolipid signaling pathway | 4.58E-03 | 6 | P17252, Q13362, Q9BX95, P10415, Q12933, Q02156 | PRKCA, PPP2R5C, SGPP1, BCL2, TRAF2, PRKCE | More | | Perhexiline | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | Perhexiline | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Perhexiline | hsa04122 | Sulfur relay system | 1.65E-02 | 1 | Q16762 | TST | More | | Perhexiline | hsa04142 | Lysosome | 2.98E-02 | 2 | P10619, P49281 | CTSA, SLC11A2 | More | | Perhexiline | hsa04145 | Phagosome | 1.59E-03 | 7 | Q15080, P14598, Q13509, P68371, Q13488, O60603, P13765 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, TLR2, HLA-DOB | More | | Perhexiline | hsa04151 | PI3K-Akt signaling pathway | 4.50E-02 | 9 | P25116, P49767, Q13362, P62873, P16144, O60603, P01568, P10415, P17252 | F2R, VEGFC, PPP2R5C, GNB1, ITGB4, TLR2, IFNA21, BCL2, PRKCA | More | | Perhexiline | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | | Perhexiline | hsa04217 | Necroptosis | 7.46E-06 | 13 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, Q6FI13, Q99878, Q93077, P10415, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, H2AC18; H2AC19, H2AC14, HIST1H2AC, BCL2, CHMP2A, PPID | More | | Perhexiline | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | | Perhexiline | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.84E-02 | 5 | P09493, Q13362, P0DP23, P17252, P10415 | TPM1, PPP2R5C, CALM1, PRKCA, BCL2 | More | | Perhexiline | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Perhexiline | hsa04540 | Gap junction | 1.29E-02 | 4 | P17252, Q13509, P68371, Q14643 | PRKCA, TUBB3, TUBB2C, ITPR1 | More | | Perhexiline | hsa04613 | Neutrophil extracellular trap formation | 6.17E-06 | 18 | P17252, P11215, O60603, P08246, Q13547, P04908, Q6FI13, Q93077, P58876, P62807, Q16778, O60814, P68431, P14598, Q15080, P21462, O43315, Q16539 | PRKCA, ITGAM, TLR2, ELA2, HDAC1, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, FPR1, AQP9, MAPK14 | More | | Perhexiline | hsa04622 | RIG-I-like receptor signaling pathway | 2.47E-02 | 1 | Q12933 | TRAF2 | More | | Perhexiline | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Perhexiline | hsa04640 | Hematopoietic cell lineage | 3.69E-02 | 4 | P21926, P07766, P01730, P09564 | CD9, CD3E, CD4, CD7 | More | | Perhexiline | hsa04672 | Intestinal immune network for IgA production | 3.76E-03 | 3 | P29965, P10747, P13765 | CD40LG, CD28, HLA-DOB | More | | Perhexiline | hsa04713 | Circadian entrainment | 2.60E-02 | 4 | P0DP23, P17252, P62873, Q14643 | CALM1, PRKCA, GNB1, ITPR1 | More | | Perhexiline | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Perhexiline | hsa04720 | Long-term potentiation | 3.89E-02 | 3 | P17252, P0DP23, Q14643 | PRKCA, CALM1, ITPR1 | More | | Perhexiline | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Perhexiline | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Perhexiline | hsa04723 | Retrograde endocannabinoid signaling | 1.88E-02 | 4 | Q14643, P17252, P62873, Q16718 | ITPR1, PRKCA, GNB1, NDUFA5 | More | | Perhexiline | hsa04725 | Cholinergic synapse | 1.88E-02 | 4 | Q14643, P17252, P62873, P10415 | ITPR1, PRKCA, GNB1, BCL2 | More | | Perhexiline | hsa04728 | Dopaminergic synapse | 3.55E-02 | 5 | Q14643, P17252, P62873, Q13362, P0DP23 | ITPR1, PRKCA, GNB1, PPP2R5C, CALM1 | More | | Perhexiline | hsa04744 | Phototransduction | 1.02E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Perhexiline | hsa04912 | GnRH signaling pathway | 3.89E-02 | 3 | P17252, Q14643, P0DP23 | PRKCA, ITPR1, CALM1 | More | | Perhexiline | hsa04922 | Glucagon signaling pathway | 3.47E-02 | 4 | Q12778, Q13370, P0DP23, Q14643 | FOXO1, PDE3B, CALM1, ITPR1 | More | | Perhexiline | hsa04924 | Renin secretion | 8.71E-03 | 3 | Q14643, Q13370, P0DP23 | ITPR1, PDE3B, CALM1 | More | | Perhexiline | hsa04930 | Type II diabetes mellitus | 2.47E-02 | 1 | Q02156 | PRKCE | More | | Perhexiline | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | Perhexiline | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.27E-02 | 5 | P42224, P10415, Q12778, P49767, P17252 | STAT1, BCL2, FOXO1, VEGFC, PRKCA | More | | Perhexiline | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Perhexiline | hsa04966 | Collecting duct acid secretion | 2.86E-02 | 2 | Q13488, Q9Y666 | TCIRG1, SLC12A7 | More | | Perhexiline | hsa04974 | Protein digestion and absorption | 2.47E-02 | 1 | Q7Z2H8 | SLC36A1 | More | | Perhexiline | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Perhexiline | hsa05010 | Alzheimer disease | 3.55E-02 | 7 | Q16718, O14521, Q14643, P0DP23, Q13509, P68371, Q08752 | NDUFA5, SDHD, ITPR1, CALM1, TUBB3, TUBB2C, PPID | More | | Perhexiline | hsa05012 | Parkinson disease | 2.25E-02 | 6 | Q16718, O14521, Q14643, P0DP23, Q13509, P68371 | NDUFA5, SDHD, ITPR1, CALM1, TUBB3, TUBB2C | More | | Perhexiline | hsa05020 | Prion disease | 1.31E-03 | 9 | Q16718, O14521, Q14643, Q13509, P68371, P49841, P14598, Q15080, Q16539 | NDUFA5, SDHD, ITPR1, TUBB3, TUBB2C, GSK3B, NCF1, NCF4, MAPK14 | More | | Perhexiline | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.00E-04 | 12 | Q14643, Q13509, P68371, P49841, P10415, Q16718, O14521, Q13561, P17252, Q16539, Q08752, P0DP23 | ITPR1, TUBB3, TUBB2C, GSK3B, BCL2, NDUFA5, SDHD, DCTN2, PRKCA, MAPK14, PPID, CALM1 | More | | Perhexiline | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Perhexiline | hsa05131 | Shigellosis | 3.33E-03 | 10 | Q12933, P68431, Q02156, Q9UDY8, Q14247, Q14643, Q12778, Q13315, P10415, Q08752 | TRAF2, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, PRKCE, MALT1, CTTN, ITPR1, FOXO1, ATM, BCL2, PPID | More | | Perhexiline | hsa05132 | Salmonella infection | 1.11E-02 | 8 | Q9UJU2, Q13489, P10415, O60603, Q9BQS8, Q13561, Q13509, P68371 | LEF1, BIRC3, BCL2, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | | Perhexiline | hsa05140 | Leishmaniasis | 1.06E-04 | 7 | P14598, P42224, P13765, O60603, P25963, P29350, Q15080 | NCF1, STAT1, HLA-DOB, TLR2, NFKBIA, PTPN6, NCF4 | More | | Perhexiline | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Perhexiline | hsa05145 | Toxoplasmosis | 1.11E-02 | 6 | P10415, Q13489, P42224, P13765, O60603, P29965 | BCL2, BIRC3, STAT1, HLA-DOB, TLR2, CD40LG | More | | Perhexiline | hsa05150 | Staphylococcus aureus infection | 8.37E-03 | 5 | P21462, O75015, Q14532, P59665, P59666 | FPR1, FCGR3B, KRT32, DEFA1; DEFA1B, DEFA3 | More | | Perhexiline | hsa05152 | Tuberculosis | 7.93E-04 | 8 | Q13488, P0DP23, P42224, O60603, P10415, P13765, P01568, Q9UDY8 | TCIRG1, CALM1, STAT1, TLR2, BCL2, HLA-DOB, IFNA21, MALT1 | More | | Perhexiline | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Perhexiline | hsa05165 | Human papillomavirus infection | 3.10E-02 | 8 | P16144, Q05086, P01568, P42224, Q13488, Q13362, Q12778, Q13315 | ITGB4, UBE3A, IFNA21, STAT1, TCIRG1, PPP2R5C, FOXO1, ATM | More | | Perhexiline | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.73E-02 | 6 | P01568, P42224, P62873, Q14643, P0DP23, Q9UJU2 | IFNA21, STAT1, GNB1, ITPR1, CALM1, LEF1 | More | | Perhexiline | hsa05168 | Herpes simplex virus 1 infection | 3.38E-03 | 12 | P25963, P01568, Q05823, P42224, Q07955, Q13243, Q13489, Q13398, Q9HCX3, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS5, BIRC3, ZNF211, ZNF304, ZNF140, ZNF189, ZNF212 | More | | Perhexiline | hsa05170 | Human immunodeficiency virus 1 infection | 4.67E-03 | 9 | P62873, P0DP23, P17252, Q14643, P01568, O60603, Q13315, P10415, Q9Y6Q5 | GNB1, CALM1, PRKCA, ITPR1, IFNA21, TLR2, ATM, BCL2, AP1M2 | More | | Perhexiline | hsa05200 | Pathways in cancer | 4.99E-02 | 12 | P42224, Q9UJU2, P17252, P14923, P10415, Q13489, P49767, Q12778, P25116, P62873, P0DP23, P01568 | STAT1, LEF1, PRKCA, JUP, BCL2, BIRC3, VEGFC, FOXO1, F2R, GNB1, CALM1, IFNA21 | More | | Perhexiline | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | | Perhexiline | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | | Perhexiline | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Perhexiline | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | | Perhexiline | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | | Perhexiline | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.09E-02 | 4 | P07766, P06239, Q9HC35, P01730 | CD3E, LCK, EML4, CD4 | More | | Perhexiline | hsa05320 | Autoimmune thyroid disease | 1.27E-03 | 4 | P13765, P29965, P01568, P10747 | HLA-DOB, CD40LG, IFNA21, CD28 | More | | Perhexiline | hsa05322 | Systemic lupus erythematosus | 2.33E-07 | 12 | P08246, P09871, P10747, P13765, P29965, Q6FI13, Q93077, P58876, P62807, Q16778, O60814, P68431 | ELA2, C1S, CD28, HLA-DOB, CD40LG, H2AC18; H2AC19, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Perhexiline | hsa05323 | Rheumatoid arthritis | 1.29E-02 | 4 | P13765, Q13488, P10747, O60603 | HLA-DOB, TCIRG1, CD28, TLR2 | More | | Perhexiline | hsa05330 | Allograft rejection | 1.04E-03 | 5 | P13765, P29965, P48023, P10747, P01375 | HLA-DOB, CD40LG, FASLG, CD28, TNF | More | | Perhexiline | hsa05332 | Graft-versus-host disease | 3.70E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Perhexiline | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | | Perhexiline | hsa05415 | Diabetic cardiomyopathy | 5.60E-05 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | | Perhexiline | hsa05416 | Viral myocarditis | 2.62E-02 | 3 | P13765, P29965, P10747 | HLA-DOB, CD40LG, CD28 | More | | |